Zhuoyi Biology secures RMB150m financing, focusing on the R&D of human rabies vaccine

Zhuoyi Biological has recently announced the completion of 150 million yuan in financing. This round of financing was led by Hidragon Capital, and joined by Shang Finance and Zhuoyi Biological management team.

Zhuoyi Biological has recently announced the completion of 150 million yuan in financing. This round of financing was led by Hidragon Capital, and joined by Shang Finance and Zhuoyi Biological management team.

The proceeds from this round of financing will be used to continue the completion of the clinical trials currently being conducted by Zhuoyi Biological, to advance a number of subsequent innovative vaccines to the clinical stage, and to accelerate the construction of the new plant to meet the future production needs of subsequent vaccines.

According to public records, Zhuoyi Biological, founded in January 2005, is a new vaccine manufacturing company that integrates research and development, production and sales.

The company’s current approved biological products are mainly lyophilized human rabies vaccine (Vero cells), with a current annual production capacity of one million copies; the second phase of the workshop was completed at the end of 2018, and the annual production capacity will be further increased after the audit and approval.

The company maintains close scientific collaboration with a number of Chinese and international research institutions, and is advancing the research and development of several innovative vaccines in an orderly manner.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/23/zhuoyi-biology-secures-rmb150m-financing-focusing-on-the-r-d-of-human-rabies-vaccine/.

Leave a Reply

Please Login to Comment